Market growth is driven mainly by factors such as increasing R&D spending by pharmaceutical & biotechnology companies, technological advancements in high-throughput screening market and the availability of government funding & venture capital investments. Emerging markets and growing applications in life sciences research are also factors expected to provide growth opportunities for players in the HTS market.
The global high-throughput screening (HTS) market size is projected to reach USD 26.4 billion by 2025 from USD 15.3 billion in 2020, at a CAGR of 11.5% during the forecast period.
The global high-throughput screening market is highly consolidated. Key players in the high-throughput screening market include Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Danaher Corporation (US), PerkinElmer, Inc. (US), Tecan Group Ltd. (Switzerland), AXXAM S.p.A. (Italy), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Promega Corporation (US), Corning Incorporated (US), and Eurofins Scientific (Luxembourg).Acquisitions and product launches are the key growth strategies undertaken by these companies to maintain their positions in the market.
Thermo Fisher Scientific Inc. (US): Thermo Fisher’s market position can be attributed to its robust product portfolio for the high-throughput screening market. To maintain its position in the high-throughput screening market, the company adopts organic and inorganic growth strategies such as product launches, agreements, joint ventures, and acquisitions. For instance, the company signed a joint venture with Innoforce Pharmaceuticals (China) to establish a new pharma services facility in Hangzhou, China, to expand its drug development & manufacturing service in China.
Agilent Technologies, Inc (US): Agilent’s strong market position in the high-throughput screening market can be attributed to its focus on inorganic growth strategies such as acquisitions. In 2019, the company expanded its growing presence and expertise in cell analysis by acquiring BioTek Instruments (US). This development also strengthened the firm’s position in the high-throughput screening market. In 2018, the company carried out four acquisitions to strengthen its position in the high-throughput screening market. Agilent also focuses on expanding its presence in developing markets such as China and India. Agilent opened a new logistics hub in Shanghai to support this strategy to conduct faster delivery of parts, supplies, and consumables to laboratories in China.
Merck KGaA (Germany) has a strong portfolio of high-throughput screening consumables, instruments, software, and services. To maintain its position in the market, the company focuses on organic and inorganic growth strategies such as product launches and agreements. For instance, in 2020, Merck opened its Largest M Lab Collaboration Center in Shanghai to focus on drug discovery, development, and manufacturing. The overall Life Science business segment achieved strong organic growth of 9.0% and 8.8% in 2019 and 2018. The revenue growth was observed in the Life Science business segment, including laboratory equipment and cell-based research products.